-
Posted by
Two Blokes May 20, 2025 -
Filed in
Stock
-
7 views
Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish, with multiple Buy ratings and price targets ranging from $22 to $45 a share on the stock that current trades around $17.00 a share. The company did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a recently submitted sNDA.
